GGrantIndex
← Leaderboards

Melanie S Joy

University Of North Carolina Chapel Hill

Google Scholar ↗PubMed ↗ORCID ↗
$4,717,709
Attributed
$8,059,580
Total exposure
14
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,059,580 · 14

By mechanism

R01$6,260,851 · 3
R21$790,791 · 2
K23$609,172 · 1
R41$350,000 · 1
M01$48,766 · 7

Top collaborators

Others in their field

Top investigators on “Pharmaceutical Preparations”

Research focus

Pharmaceutical PreparationsKidneyDrug KineticsResponseToxic EffectIn VivoAffectRenal FunctionRegimenPhenotypeEnzymesBaseMediatingExposure ToClinical ResearchIn VitroAnimalsCytochrome P450DoseSerumBiological MarkersKidney DiseasesMalignant NeoplasmsClinical Practice

Grant awards (31)

Preclinical and Clinical Models of Drug Induced Kidney Injury$623,715
R01 · FY2025 · CA · contact PI
Novel Extracorporeal Technology for Kidney Disease$350,000
R41 · FY2025 · DK · contact PI
Preclinical and Clinical Models of Drug Induced Kidney Injury$596,308
R01 · FY2024 · CA · contact PI
Preclinical and Clinical Models of Drug Induced Kidney Injury$637,693
R01 · FY2023 · CA · contact PI
Diversification of Glomerular Kidney Disease Treatments By Targeting Therapeutics to the Kidney$367,900
R21 · FY2023 · AR · contact PI
Drug Disposition and Nephrotoxicity$471,738
R01 · FY2021 · GM
Drug Disposition and Nephrotoxicity$502,771
R01 · FY2020 · GM
Drug Disposition and Nephrotoxicity$494,541
R01 · FY2019 · GM
Drug Disposition and Nephrotoxicity$136,400
R01 · FY2019 · GM
Drug Disposition and Nephrotoxicity$528,688
R01 · FY2018 · GM
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease$438,433
R01 · FY2018 · GM · contact PI
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease$450,298
R01 · FY2017 · GM · contact PI
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease$474,526
R01 · FY2016 · GM · contact PI
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease$435,128
R01 · FY2015 · GM · contact PI
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease$470,612
R01 · FY2014 · GM · contact PI
Pharmacokinetic and Pharmacogenomic Determinants of Cisplatin Kidney Injury$185,391
R21 · FY2013 · DK · contact PI
Pharmacokinetic and Pharmacogenomic Determinants of Cisplatin Kidney Injury$237,500
R21 · FY2012 · DK · contact PI
Pharmacokinetics & Genomics in Glomerular Diseases$128,116
K23 · FY2008 · DK · contact PI
PHARMACOGENIC REASONS FOR POOR LUPUS NEPHRITIS OUTCOMES$8,188
M01 · FY2008 · RR · contact PI
P-GLYCOPROTEIN AND CYTOCHROME P450 GENOTYPE AND PHENOTYPE ON RESPONSE TO ANCA$3,520
M01 · FY2008 · RR · contact PI
Pharmacokinetics & Genomics in Glomerular Diseases$117,188
K23 · FY2007 · DK · contact PI
PHARMACOGENIC REASONS FOR POOR LUPUS NEPHRITIS OUTCOMES$18,383
M01 · FY2007 · RR · contact PI
P-GLYCOPROTEIN AND CYTOCHROME P450 GENOTYPE AND PHENOTYPE ON RESPONSE TO ANCA$9,754
M01 · FY2007 · RR · contact PI
Pharmacokinetics & Genomics in Glomerular Diseases$116,078
K23 · FY2006 · DK · contact PI
PHARMACOGENIC REASONS FOR POOR LUPUS NEPHRITIS OUTCOMES$6,443
M01 · FY2006 · RR · contact PI
P-GLYCOPROTEIN AND CYTOCHROME P450 GENOTYPE AND PHENOTYPE ON RESPONSE TO ANCA$2,478
M01 · FY2006 · RR · contact PI
Pharmacokinetics &Genomics in Glomerular Diseases$120,674
K23 · FY2005 · DK
Pharmacokinetics &Genomics in Glomerular Diseases$127,116
K23 · FY2004 · DK
ATORVASTATIN ON LIPID PROFILES &LIPOPROTEIN IN DIALYSIS PTS$0
M01 · FY2000 · RR
ATORVASTATIN ON LIPID PROFILES &LIPOPROTEIN IN DIALYSIS PTS$0
M01 · FY2000 · RR
ATORVASTATIN ON LIPID PROFILES &LIPOPROTEIN IN DIALYSIS PTS$0
M01 · FY2000 · RR